Denali Therapeutics (DNLI) Interest Coverage Ratio (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Interest Coverage Ratio of 242.68 for Q1 2026, down 383.43% year-over-year from 85.62 in Q1 2025, and down 426.47% quarter-over-quarter from 46.1 in Q4 2025.
Denali Therapeutics (DNLI) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Interest Coverage Ratio for 10 consecutive years, with 242.68 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 383.43% year-over-year to 242.68; the TTM figure through Mar 2026 stood at 966.64 (down 2062.16% YoY), while the FY2025 annual figure was 39.36, down 3838.54% from the prior year.
- Interest Coverage Ratio declined to 242.68 in Q1 2026 per DNLI's latest filing, from 46.1 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 61.7 in Q2 2023 and bottomed at 242.68 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 43.88 across 5 years, with a median of 40.85 in 2024.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio surged 368.85% — and 2026, when it tumbled 383.43%.
- Denali Therapeutics' Interest Coverage Ratio stood at 35.16 in 2022, then plunged by 34.99% to 47.47 in 2023, then rose by 5.18% to 45.01 in 2024, then retreated by 2.42% to 46.1 in 2025, then sank by 426.47% to 242.68 in 2026.
- Business Quant data shows DNLI's Interest Coverage Ratio at 242.68 in Q1 2026, 46.1 in Q4 2025, and 46.12 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -43.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.51 |
| Mar 31, 2026 | -242.68 |
| Dec 31, 2025 | -46.10 |
| Sep 30, 2025 | -46.12 |
| Jun 30, 2025 | -2.81 |
| Mar 31, 2025 | -50.20 |
| Dec 31, 2024 | -45.01 |
| Sep 30, 2024 | -42.70 |
| Jun 30, 2024 | -40.85 |
| Mar 31, 2024 | -42.15 |
| Dec 31, 2023 | -47.47 |
| Sep 30, 2023 | -40.74 |
| Jun 30, 2023 | 61.70 |
| Mar 31, 2023 | -40.33 |
| Dec 31, 2022 | -35.16 |
| Sep 30, 2022 | -37.08 |
| Jun 30, 2022 | -22.95 |
| Mar 31, 2022 | -25.40 |
| Dec 31, 2021 | -29.45 |
| Sep 30, 2021 | -32.69 |